With the Memorial Sloan Kettering Cancer Center as a shareholder and two Phase-2 product candidates intended for the treatment of Cancer, Y-mAbs (YMAB) seems a name that institutions need to assess. In addition, the company has tons of cash, no financial debt and no convertible securities, which seems very beneficial. The only caveat to be kept in mind is that the FDA approval could arrive somewhat late, in 2020. Investors will need to wait for the stock catalyst.
Source: Prospectus
Y-mAbs will retain the attention of many institutional investors after they check the investment banks